Zydus Lifesciences and Sunshine Healthcare Lanka Limited have mutually decided to extend the closing date for their 50:50 joint venture, ZyduS Sunshine Lifesciences (Private) Limited, to December 2026. The extension was formalized through a letter executed on October 1, 2026.

Background of the Joint Venture

The transaction involves the subscription of 50% of the total paid-up equity share capital of ZyduS Sunshine. This arrangement stems from the Share Subscription and Shareholders' Agreement (SSSHA) executed between Zydus Lifesciences, Sunshine Healthcare Lanka, and the joint venture entity. Upon completion, ZyduS Sunshine will operate as a 50:50 joint venture between the two pharmaceutical companies.

The initial intimation regarding this investment was made on June 26, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reasons for Extension

According to the company's disclosure, both parties are still in the process of completing the condition precedents outlined in the SSSHA. These conditions must be satisfied before the final subscription and transfer of shares can occur. Consequently, the timeline for the transaction has been revised to allow sufficient time for these regulatory and operational requirements to be met.

Regulatory Compliance

The update was filed with BSE Limited and National Stock Exchange of India Limited by Dhaval N. Soni, Company Secretary and Compliance Officer at Zydus Lifesciences. The filing references SEBI Master Circular dated January 30, 2026, ensuring transparency regarding material changes in the company's strategic partnerships.

Zydus Lifesciences reported that a recent USFDA cGMP inspection at its manufacturing facility in Ahmedabad concluded with a single observation. The inspection, conducted between September 21 and September 28, 2026, resulted in no findings related to data integrity.

The company stated it will work closely with the USFDA to address the identified observation expeditiously. This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring timely information dissemination to investors.

Inspection details

The regulatory review focused on current Good Manufacturing Practices (cGMP) at the company's Special Economic Zone (SEZ) II unit in Ahmedabad. The presence of only one observation suggests a generally compliant operational environment, although specific details of the observation were not disclosed in the press release.

Regulatory compliance context

The absence of data integrity observations is a critical metric for pharmaceutical companies facing USFDA scrutiny, as such issues often lead to severe regulatory actions including import alerts or consent decrees. By confirming zero data integrity findings, Zydus mitigates immediate risks associated with its export operations from this specific facility. The company’s commitment to resolving the single remaining observation indicates a standard remediation process rather than a systemic compliance failure.